


10/ST/90



06/15/01 A

Attorney Docket No.:

A-415H

DIVISION - CONTINUATION - CONTINUATION-IN-PART
APPLICATION TRANSMITTAL FORMJC978 US 882725 PRO
06/15/01

JUN 15 2001

Anticipated Classification Of This Application: Class	Subclass	Prior Application: Examiner Ulm, J.	Art Unit 1646
--	----------	---	------------------

To the Assistant Commissioner for Patents:

This is a request for filing a continuation divisional continuation-in-part application, under 37 CFR 1.53(b), of pending prior application Serial No. 09/214,613 filed on January 8, 1999, of Fisher et al.

for Truncated Soluble Tumor Necrosis Factor Type-I and Type-II Receptors

For CONTINUATION or DIVISIONAL APPLNs only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 1b, below, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

1. Transmitted herewith are:
 - 148 pages of specification, 9 pages of claim(s) and 1 page of abstract, **totaling** 158 pages.
 - 13 sheet(s) of drawings.
 - 4 pages of Oath or Declaration by the applicant(s):
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 CFR 1.63(d)) (*for continuation/divisional applns. only*)
 - 34 pages of Sequence Listing; sequence statement.
2. The filing fee is calculated below:

For	Number Filed		Number Extra	Rate	Fee
Total Claims	37	- 20 =	17	x \$18.00 =	\$ 306.00
Independent Claims	4	- 3 =	1	x \$80.00 =	80.00
Multiple Dependent Claims	0			+ \$270.00 =	0.00
Basic Fee				\$710.00 =	710.00
				Total Filing Fee	\$1,096.00

3. Please charge Deposit Account No. 01-0519, in the name of Amgen Inc., in the amount of **\$1,096.00**.
An original and one copy are enclosed.
4. Throughout the prosecution of this application, if any extension of time is necessary, please consider this a request therefor.
5. The Commissioner is hereby authorized to charge any additional filing fees which may be required by the accompanying application, any additional fees which may be required during pendency of this application as required by 37 CFR 1.16 or 1.17, or credit any overpayment to Deposit Account No. 01-0519 throughout the prosecution of this application.
6. Cancel in this application original claims
of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

EXPRESS MAIL CERTIFICATE

'Express Mail' mail labeling number EL360689872USDate of Deposit June 15, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office to Addressee' service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application Assistant Commissioner for Patents Washington, D.C. 20231

RONDA G. SPAHR

Printed Name

Ronda G. Spahr

Signature

7. Preliminarily, please amend the specification by inserting before the first line the following:

--This application is a continuation division of application Serial No. 09/214,613, filed January 8, 1999, which is a 35 USC 371 filing of International Application No. PCT/US97/12244, filed July 9, 1997, which claims the benefit of U.S. Provisional Application Nos. 60/021,443, filed July 9, 1996; 60/032,534, filed December 6, 1996; 60/037,737, filed January 23, 1997; 60/039,314, filed February 7, 1997 and 60/039,792, filed March 4, 1997, which are hereby incorporated by reference.--

8. Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.
(May only be used if signed by person authorized by § 1.138 and before payment of base issue fee.)

8a. New formal drawings are enclosed.

9. Priority of application Serial No. _____ filed on _____ in _____
is claimed under 35 USC 119.

9a. The certified copy has been filed in prior application Serial No. _____ filed _____

10. The prior application is assigned of record to Amgen Inc.

11. A preliminary amendment is enclosed.

12. Also enclosed _____

13. Other: _____

14. The power of attorney in the prior application is to:

Ron K. Levy, Reg. No. 31,539,

Steven M. Odre, Reg. No. 29,094 and

Thomas D. Zindrick, Reg. No. 32,185

- a. The power appears in the original papers in the prior application (**copy attached**).
- b. Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. Address all future communications to
Thomas D. Zindrick
at the address below.

Signator: Assignee of complete interest

Attorney or agent of record

Thomas D. Zindrick
Attorney/Agent for Applicant(s)
Registration No. 32,185
Phone: (805) 447-8101
Date: June 15, 2001

Please send all future correspondence to:

U. S. Patent Operations/ TDZ
Dept 4300, M/S 27-4-A
AMGEN, INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799, USA



21069

PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Fisher et al.

Serial No.: To Be Assigned

Filed: June 15, 2001

For: Truncated Soluble Tumor Necrosis Factor Type-I and Type-II Receptors

Docket No.: A-415H

ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821(e)


Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The computer readable form in this application, Serial No. UNASSIGNED, is identical with that filed in Application Serial No. 09/214,613, filed January 8, 1999. In accordance with 37 CFR §1.821(e), please use the first-filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included herewith.

In addition, I hereby state that the paper copy of the Sequence Listing in this application and the computer readable form of the Sequence Listing submitted in the parent case are the same and contains no new matter.

Respectfully submitted,




Thomas D. Zindrick
Attorney/Agent for Applicant(s)
Registration No.: 32,185
Phone: (805) 447-8101
Date: June 15, 2001

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number EL360689872US Date of Deposit June 15 2001
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to Box Patent Application Assistant Commissioner for Patents Washington D.C. 20231

Printed Name

RONDA G. SPAHR


Signature

Attorneys Statement (37 CFR 1.821(e))

Please send all future correspondence to:

US Patent Operations/ TDZ
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799